Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.64 and traded as high as $7.15. Achieve Life Sciences shares last traded at $6.32, with a volume of 718,288 shares changing hands.
Analysts Set New Price Targets
Several equities analysts have commented on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Achieve Life Sciences in a report on Friday, March 17th. Maxim Group restated a “buy” rating and set a $8.00 target price on shares of Achieve Life Sciences in a research report on Friday, March 17th.
Achieve Life Sciences Stock Up 5.9 %
The company has a market cap of $113.32 million, a P/E ratio of -1.56 and a beta of 1.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.27 and a quick ratio of 1.27. The business’s 50 day moving average price is $4.99 and its 200-day moving average price is $3.64.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last posted its quarterly earnings data on Thursday, March 16th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.07. During the same period last year, the business posted ($0.76) earnings per share. On average, analysts anticipate that Achieve Life Sciences, Inc. will post -1.94 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Achieve Life Sciences
A number of institutional investors have recently modified their holdings of ACHV. Long Focus Capital Management LLC increased its holdings in shares of Achieve Life Sciences by 73.6% in the third quarter. Long Focus Capital Management LLC now owns 308,220 shares of the biopharmaceutical company’s stock valued at $1,017,000 after purchasing an additional 130,624 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Achieve Life Sciences by 48.4% during the fourth quarter. LPL Financial LLC now owns 148,300 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 48,400 shares during the period. Raymond James & Associates boosted its holdings in Achieve Life Sciences by 412.0% in the fourth quarter. Raymond James & Associates now owns 89,249 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 71,818 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Achieve Life Sciences by 57.5% in the second quarter. Renaissance Technologies LLC now owns 39,700 shares of the biopharmaceutical company’s stock valued at $194,000 after acquiring an additional 14,500 shares during the last quarter. Finally, Citadel Advisors LLC increased its position in Achieve Life Sciences by 33.2% in the third quarter. Citadel Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 8,725 shares during the period. 21.11% of the stock is owned by institutional investors.
About Achieve Life Sciences
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.